BioVentix PLC Posting of Annual Report and Notice of AGM (1402T)

TIDMBVXP

RNS Number : 1402T

BioVentix PLC

10 November 2023

Bioventix plc

("Bioventix" or the "Company")

Posting of Annual Report and Notice of AGM

Bioventix plc (AIM: BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that it has today posted its Annual Report for the year ended 30 June 2023 together with a Notice of Annual General Meeting ("AGM") and Form of Proxy to shareholders that have elected to receive documentation in hard copy format. The documents will also be available from the Company's website at www.bioventix.com under the Investors section.

The Company's AGM will be held at Farnham Castle, Farnham, Surrey, GU9 0AG on Thursday 7 December 2023 at 2.00pm.

For further information please contact:

 
Bioventix plc                                                Tel: 01252 728 001 
 Peter Harrison                     Chief Executive Officer 
 
Cavendish Capital Markets Limited                            Tel: 020 7220 0500 
 Geoff Nash/Simon Hicks             Corporate Finance 
 Nigel Birks/Harriet Ward           ECM

About Bioventix plc:

Bioventix (www.bioventix.com) specialises in the development and commercial supply of high-affinity monoclonal antibodies with a primary focus on their application in clinical diagnostics, such as in automated immunoassays used in blood testing. The antibodies created at Bioventix are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. Bioventix currently offers a portfolio of antibodies to customers for both commercial use and R&D purposes, for the diagnosis or monitoring of a broad range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. Bioventix currently supplies antibody products and services to the majority of multinational clinical diagnostics companies. Bioventix is based in Farnham, UK and its shares are traded on AIM under the symbol BVXP.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NOAQBLFFXFLFFBK

(END) Dow Jones Newswires

November 10, 2023 11:23 ET (16:23 GMT)

Bioventix (AQSE:BVXP.GB)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024